Comorbidities¶
Trans women carry roughly a two- to four-fold elevation in nearly every common psychiatric diagnosis relative to cis peers. The mechanism is largely Minority Stress, not anything intrinsic to being trans — but the elevated prevalence has practical implications: more patients need psychiatric medication, and several common psych meds interact with HRT in ways the average prescriber did not learn in training.
The clinically important interactions are mostly pharmacodynamic, not CYP-mediated: SSRIs that stack onto HRT-induced sexual side effects, SNRIs that nudge an already-elevated VTE risk, lithium plus spironolactone competing for renal handling, stimulants stacking on estrogen-modulated cardiovascular load, and antipsychotics whose hyperprolactinemia is amplified by estrogen.
For acute risk see Suicide & Safety Planning. For substance use see Substance Use. For disordered eating in the context of body change goals see Body Image.
Prevalence: the baseline that shapes everything else¶
Comorbid psychiatric burden in transfeminine populations is not a subtle effect.
| Population / cohort | Finding | n |
|---|---|---|
| 2015 US Transgender Survey (James 2016) | 39% serious past-month psychological distress | 27,715 |
| 2015 USTS | 40% lifetime suicide attempt (vs ~4.6% cis adults) | 27,715 |
| 2022 USTS Early Insights (NCTE 2024) | Reproduced 2015 distress and attempt figures | 92,329 |
| ENIGI follow-up (Defreyne 2023) | ~50% met mood/anxiety criteria at HRT baseline | cohort |
| UK gender clinic (Witcomb 2018) | 38% lifetime depression, 35% anxiety in trans women | 913 |
The minority-stress framework (Meyer 2003; Hendricks & Testa 2012) is the dominant explanatory model: chronic discrimination, family rejection, and identity concealment drive the elevation, and prevalence drops measurably after social and medical transition. This matters clinically because (1) HRT itself often improves mood symptoms enough to allow medication reduction, and (2) the trauma history that drove the comorbidity is often still active and shapes treatment response.
HRT changes the prescribing picture
Many patients arrive on psych meds chosen pre-transition for a body and life that no longer exist. A medication review at 6 and 12 months post-HRT-start should be routine — depression and anxiety scores fall significantly over the first year (Defreyne 2020), and dose reductions or switches are often appropriate.
Depression¶
Lifetime prevalence runs 30–50% across major trans cohorts. Treatment follows standard psychiatric guidelines, but drug choice has trans-specific considerations that change which first-line agent is actually best.
SSRIs and SNRIs¶
SSRIs are first-line. Sertraline (50–200 mg) and escitalopram (10–20 mg) are preferred for cleaner CYP profiles. Citalopram is a close second; QT limits doses above 20 mg with other QT-prolonging drugs. Fluoxetine's CYP2D6 inhibition matters when stacked with atomoxetine, tricyclics, or some antipsychotics.
The dominant trans-specific concern is sexual side effects. SSRIs cause anorgasmia, delayed ejaculation, and reduced libido in 30–60% of users (Montejo 2001; Clayton 2002), and HRT itself reduces libido and ejaculatory volume on Anti-androgens and Estrogens. The two effects stack additively, and patients sometimes interpret SSRI-induced change as HRT progress — delaying medication adjustment and body-mapping.
SNRIs (venlafaxine 75–225 mg, duloxetine 30–120 mg) are second-line. The trans-specific concern is estrogen-mediated VTE (~2% lifetime prevalence on GAHT, highest in year one; Totaro 2021). SNRIs raise BP modestly with weak prothrombotic associations — not contraindicated, but with stacked risk (smoking, obesity, prior thrombosis, oral CEE) prefer SSRIs or transdermal E.
| Drug class | First-line picks | Trans-specific watch | When to avoid |
|---|---|---|---|
| SSRI | Sertraline, escitalopram | Sexual side effects stack with HRT | After SSRI failure for sexual dysfunction |
| SNRI | Venlafaxine, duloxetine | Modest BP/VTE signal | Stacked VTE risk on oral CEE |
| NDRI | Bupropion XL | Seizure threshold; ED contraindication | Active anorexia or bulimia |
| Atypical | Mirtazapine, vortioxetine | Weight gain (mirtazapine) | When weight loss is undesired (mirtazapine helps) |
| Tricyclic | Nortriptyline (low anticholinergic) | Anticholinergic, QT, weight | First-line use; reserve for refractory or pain |
| MAOI | Tranylcypromine, phenelzine | Diet/drug interactions; orthostasis | Without specialist supervision |
Bupropion¶
150–450 mg XL. Benign sexual side-effect profile, rescues SSRI-induced anorgasmia at 150 mg, doubles as smoking-cessation pharmacotherapy in a population with elevated smoking prevalence and smoking-driven CV risk on estrogen, and lacks the weight-gain liability of SSRIs. Seizure threshold is the standard caveat (IR >450 mg historical risk driver).
Bupropion is contraindicated in active eating disorders
Active bulimia and current/historical anorexia are firm contraindications. Given 17.6% past-year ED prevalence in trans students (Diemer 2015) and 8.1% lifetime clinician-diagnosed EDs in trans women (Nagata 2020), screen explicitly before prescribing — not as part of a broader review-of-systems but as a deliberate question about restriction, purging, and binge patterns. See the eating disorders section below.
Tricyclics and mirtazapine¶
Tricyclics are uncommon for primary depression but still appear for chronic pain, migraine prophylaxis, and treatment-resistant depression. Anticholinergic burden, orthostasis, and QT are the standard caveats; the weight-gain effect compounds HRT-related body-composition changes. Mirtazapine works as a bridge agent for comorbid insomnia or unwanted weight loss — appetite stimulation is reliable. MAOIs remain effective for refractory depression with no HRT-specific twist beyond the standard washout requirements.
Anxiety disorders¶
GAD, panic disorder, and social anxiety are roughly 1.5–2× more prevalent, with social anxiety especially elevated in pre-transition or early-transition patients where passing concerns drive avoidance. SSRIs and SNRIs are first-line; the prescribing logic is identical to depression.
Benzodiazepines¶
Alprazolam, clonazepam, and lorazepam do not interact pharmacokinetically with HRT, but two practical concerns apply:
- PRN context. Procedure-related anxiety (injections, electrolysis, pre-op visits) is a common indication. Trans populations have elevated substance-use comorbidity (Hughto 2021), favoring short-course or strict PRN over scheduled dosing.
- Sedation stacking. Cyproterone-related fatigue and benzodiazepine sedation compound. Patients on CPA who feel "flat" often improve on lower benzo dosing before changing antidepressants.
Buspirone, hydroxyzine, gabapentin, and propranolol are safer chronic options.
PTSD and complex PTSD¶
PTSD prevalence runs 20–40%, roughly four times the cis-population rate (Reisner 2016; Shipherd 2011). Complex PTSD from chronic invalidation, family rejection, or interpersonal violence is overrepresented and shapes treatment in ways simple PTSD does not.
Sertraline and paroxetine are FDA-approved; venlafaxine has reasonable evidence; prazosin (1–10 mg qhs) for nightmares is widely used and does not interact with HRT.
Trauma-focused psychotherapy is the load-bearing intervention. EMDR, prolonged exposure, and cognitive processing therapy all have evidence in trans populations (Mizock 2008; Walker & Zeligman 2019).
Gender-affirming care can re-expose prior trauma
HRT and surgical-letter encounters re-expose patients to gatekeeping experiences that overlap with prior trauma, particularly for those whose trauma is already medical or institutional. Clinicians treating comorbid PTSD should coordinate with HRT prescribers on pacing, body exam practices, and consent language. MDMA-assisted therapy data in trans populations is emerging; no specific HRT interaction is documented, though MDMA's serotonergic load means standard SSRI washout protocols apply.
Eating disorders¶
Eating disorders are markedly elevated, with effect sizes of roughly 2–4× cis peers. Diemer 2015 (n=289,024 college students) found 17.6% past-year diagnosed ED in trans students versus ~1.85% in cis heterosexual women. Nagata 2020 found 8.1% lifetime clinician-diagnosed EDs in trans women specifically, with restrictive presentations dominant. Coelho 2024 confirmed the pattern in systematic review. Duffy 2019 found 75% of trans students with EDs had attempted suicide in the past year — the comorbidity is dangerous in ways that exceed either condition alone.
The mechanism is partly minority stress and partly something more specific: dysphoria-driven restriction, where the body-altering effect of weight loss is desired, mapping onto feminization goals through fat-pattern shift. The qualitative literature (Cusack 2022) describes how this reframes restriction as instrumental and makes standard ED treatment frameworks — which assume the patient wants their body restored to its pre-illness state — partially inapplicable.
Inpatient ED programs are often poorly equipped for trans patients
Gendered units, body-focused interventions, and weight-restoration goals that conflict with feminization make standard inpatient ED programming actively counter-therapeutic for many trans patients. Specialist programs (Reasons, ERC, Equip) have begun building trans-affirming tracks but capacity is limited. ED screening should precede any weight-management discussion, including the intentional weight-cycling practice common in transfeminine spaces, which is a recognized vector pushing vulnerable patients into clinical disorder.
Pharmacotherapy considerations specific to ED comorbidity:
- Bupropion — contraindicated in active bulimia and anorexia.
- Olanzapine for AN weight restoration — prolactin and metabolic effects amplified by estrogen.
- Fluoxetine 60 mg — only FDA-approved ED indication.
- Refeeding — electrolyte shifts can affect spironolactone safety (hyperkalemia) and lithium clearance.
ADHD¶
ADHD is more prevalent in trans populations broadly, with a particularly sharp elevation in the autism-trans overlap subgroup (Warrier 2020 found trans adults 3–6× more likely to be autistic, and autism carries high ADHD comorbidity). Strazdins 2024 estimated combined ADHD prevalence in trans adults at ~15–25% versus ~5% in the general adult population.
Stimulants on estrogen¶
Methylphenidate and amphetamines are first-line. Both raise HR (5–10 bpm) and BP (3–8 mmHg systolic). Estrogen is not pro-arrhythmic per se, but transfeminine patients have elevated CV event rates over decades on HRT (Nota 2019 found ~2× ischemic stroke and MI rates, hazards concentrated in oral CEE users), and stimulants compound this.
The clinical rule: do not avoid stimulants, but layer the monitoring. Get baseline ECG and BP in patients with any CV history, recheck after titration, and prefer transdermal estradiol with stacked CV risk. No direct CYP interaction with estradiol.
Non-stimulants¶
Atomoxetine, guanfacine, and bupropion (off-label) are reasonable alternatives. Guanfacine's blood-pressure-lowering can usefully offset stimulant effects in combination regimens. Atomoxetine has CYP2D6 dependence; coadministration with paroxetine or fluoxetine raises levels meaningfully.
Bipolar disorder¶
Prevalence appears modestly elevated (~3–5% vs ~1–2% in the general population) but the data are thinner than for unipolar depression. The clinical stakes are higher because several mood stabilizers have specific HRT interactions.
| Mood stabilizer | HRT-specific concern | Practical disposition |
|---|---|---|
| Lithium | Spironolactone reduces renal clearance | Compatible with monitoring; consider AA switch if monitoring is hard |
| Lamotrigine | Modern 17β-estradiol minimal induction | Preferred mood stabilizer in transfeminine bipolar |
| Valproate | Weight, alopecia, metabolic stacking with HRT | Avoid if alternatives exist |
| Quetiapine | Modest prolactin, metabolic load | Acceptable; monitor weight and lipids |
| Lurasidone | Best metabolic profile of atypicals | Reasonable when atypical needed |
| Olanzapine | Strong metabolic and prolactin effects | Reserve for refractory cases |
Lithium plus spironolactone¶
The most-discussed interaction. Spironolactone reduces lithium clearance against lithium's narrow therapeutic window. Not contraindicated but requires baseline and serial creatinine and lithium levels every 3–6 months, stable dosing before cross-titration, and attention to dehydration. Switching the anti-androgen to bicalutamide or a GnRH agonist bypasses the renal interaction when monitoring is logistically difficult; CPA bypasses it too but carries its own depression risk.
Lamotrigine¶
50–400 mg. Safe with HRT and often the preferred mood stabilizer in transfeminine bipolar patients. Ethinyl estradiol induces lamotrigine glucuronidation and lowers serum levels ~50% (Sabers 2003); modern transfeminine HRT uses 17β-estradiol with a smaller induction effect, but levels can still drift on initiation — recheck at 4–6 weeks if seizure indication.
Schizophrenia and psychotic disorders¶
Rare in absolute terms but worth addressing because the interactions are substantive. Antipsychotic-induced hyperprolactinemia is the central concern.
| Antipsychotic | Prolactin on HRT | Disposition |
|---|---|---|
| Aripiprazole, brexpiprazole | Lowers or neutral | Preferred |
| Olanzapine, quetiapine | Modest rise | Acceptable; metabolic watch |
| Risperidone, paliperidone, amisulpride | Marked rise (50–200 ng/mL) | Avoid if alternatives |
| Clozapine | Minimal prolactin | No HRT contraindication |
Estrogen is itself a prolactin-raising agent (typical transfeminine prolactin on HRT runs 15–40 ng/mL). Stacked with a strong D2 blocker, prolactin can climb into the range that triggers macroadenoma workup and produces galactorrhea, sexual dysfunction, and bone-density concerns. Aripiprazole and brexpiprazole are partial agonists and either neutral or prolactin-lowering — preferred where psychosis treatment is required alongside HRT.
HRT-mood interactions¶
Beyond drug-drug interactions, HRT itself reshapes mood — sometimes enough to obviate or trigger psychiatric medication.
Estrogen¶
Mood effects are usually positive. The Defreyne 2020 ENIGI mood data showed depression and anxiety scores falling significantly over the first 3–12 months of HRT in transfeminine patients, with the effect partly attributable to dysphoria reduction and partly to estradiol's direct serotonergic and BDNF-related actions.
A subset of patients (~10–20%) experience mood lability in the first weeks of HRT or around dose changes, similar to cis-female premenstrual or perimenopausal patterns. Stable dosing — especially injection regimens that avoid peak-trough swings — helps. Supraphysiologic estradiol does not produce better mood and may worsen lability.
Anti-androgens¶
Mood effects vary sharply by drug:
| Anti-androgen | Mood signal | Clinical note |
|---|---|---|
| Cyproterone | Documented depression risk; fatigue, low libido | Consider switch in patients with depression history; meningioma risk too |
| Spironolactone | Mood-neutral; minimal BBB penetration | "Flat" reports usually trace to volume depletion at higher doses |
| Bicalutamide | No documented mood effect | Hepatotoxicity is the watch, not mood |
| GnRH agonists | Rare ADT-style depressive symptoms with concurrent E2 | Usually well-tolerated when estradiol is in range |
CPA is the anti-androgen most likely to drive a depression workup
1990s/2000s data on CPA in cis-male sex offenders and prostate-cancer patients showed clinically meaningful depression rates, and transfeminine patients on CPA report fatigue, low libido beyond estradiol alone, and depressive symptoms with some frequency. Mechanism is partly progestogenic CNS effects, partly deeper testosterone suppression. Patients who develop new depressive symptoms after starting CPA — especially without other life stressors — should be evaluated for an anti-androgen switch before being committed to long-term antidepressant therapy. The meningioma dose-cap concern (covered on Anti-androgens) is a separate reason to keep CPA dosing low.
Progesterone¶
The most mood-variable HRT component. Some patients describe improved sleep, libido, and emotional stability; others report sedation, depressive symptoms, or cyclical mood patterns familiar to cis women on progestin contraceptives. Oral micronized progesterone tends to be better tolerated than synthetics.
Sources¶
- James SE et al. Report of the 2015 U.S. Transgender Survey. NCTE, 2016.
- 2022 U.S. Transgender Survey Early Insights Report. NCTE, 2024.
- Coleman E et al. WPATH Standards of Care v8. Int J Transgend Health 2022;23(sup1).
- Hembree WC et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons. Endocrine Society. JCEM 2017;102(11):3869–3903.
- Witcomb GL et al. Levels of depression in transgender people. J Affect Disord 2018;235:308–315.
- Defreyne J et al. Mood and sexual desire in transgender persons: ENIGI. J Sex Med 2020;17(4):812–823.
- Defreyne J et al. Mental health changes in trans persons starting GAHT. J Psychosom Res 2023.
- Meyer IH. Prejudice, social stress, and mental health in LGB populations. Psychol Bull 2003;129(5):674–697.
- Hendricks ML, Testa RJ. Clinical framework for transgender clients. Prof Psychol 2012;43(5):460–467.
- Reisner SL et al. Mental health of transgender youth. J Adolesc Health 2015;56(3):274–279.
- Shipherd JC et al. Potentially traumatic events in a transgender sample. Traumatology 2011;17(2):56–67.
- Diemer EW et al. Gender identity, sexual orientation, and eating-related pathology in college students. J Adolesc Health 2015;57(2):144–149.
- Nagata JM et al. Eating disorders in sexual minorities. Curr Psychiatry Rep 2020;22(8):42.
- Coelho JS et al. Eating disorders in transgender and gender-diverse populations: systematic review. Int J Eat Disord 2024.
- Duffy ME et al. Transgender clients and eating disorders. Eat Disord 2019;27(2):169–181.
- Cusack CE et al. Reframing eating disorders in trans populations. Body Image 2022.
- Montejo AL et al. Sexual dysfunction with antidepressants. J Clin Psychiatry 2001;62(suppl 3):10–21.
- Clayton AH et al. Sexual dysfunction with newer antidepressants. J Clin Psychiatry 2002;63(4):357–366.
- Totaro M et al. VTE in transgender people on hormone therapy: meta-analysis. J Sex Med 2021.
- Nota NM et al. Acute cardiovascular events in transgender individuals. Circulation 2019;139(11):1461–1462.
- Hughto JMW et al. Substance use and mental health among transgender adults. Drug Alcohol Depend 2021.
- Sabers A et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2003;55(1–2):101–105.
- Warrier V et al. Autism in trans/gender-diverse individuals. Nat Commun 2020;11:3959.
- Strazdins E et al. ADHD prevalence in transgender adults: scoping review. Front Psychiatry 2024.